In this discussion of ‘commercially reasonable efforts,’ Dr. Greg Bell explains how understanding the strategy behind a pharmaceutical product launch can inform development obligations in contract and licensing agreements. Click below to read the article.
Keytruda & PD-(L)1: Life after programmed death (Part 3)
As several market-leading PD-(L)1 inhibitors face imminent loss of exclusivity (LoE), the industry confronts a stark reality: technological innovation alone no...